GLP1R and type 2 diabetes mellitus: A limitation of the current stratified approach to SGLT2i and GLP1-RA treatment in clinical guidelines is that is informed by trial recruitment strategies, and consequential accumulation of evidence of treatment benefits only for specific subgroups with or at high risk of cardiorenal disease, rather than from an understanding of how the benefits and risks of each drug class vary across the whole spectrum of T2D.